Overview

Useful For
Predicting fetal lung maturity and assessing the risk of developing neonatal respiratory distress syndrome, when performed during 32 to 39 weeks gestation

Method Name
Sysmex XN-9000, Platelet Count by Impedance Method

NY State Available
Yes

Specimen

Specimen Type
Amniotic Fld

Specimen Required
Container/Tube: Amniotic fluid container or plastic vial

Specimen Volume: 2 mL

Collection Instructions:
1. Do not centrifuge
2. Amniotic specimens must be blood and meconium free.

Specimen Minimum Volume
0.75 mL

Reject Due To

<table>
<thead>
<tr>
<th></th>
<th>Mild reject; Gross reject</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemolysis</td>
<td></td>
</tr>
<tr>
<td>Lipemia</td>
<td>NA</td>
</tr>
<tr>
<td>Icterus</td>
<td>NA</td>
</tr>
<tr>
<td>Other</td>
<td>Centrifuged specimen. Presence of blood or meconium</td>
</tr>
</tbody>
</table>

Specimen Stability Information

<table>
<thead>
<tr>
<th>Specimen Type</th>
<th>Temperature</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amniotic Fld</td>
<td>Refrigerated (preferred)</td>
<td>28 days</td>
</tr>
<tr>
<td></td>
<td>Ambient</td>
<td>7 days</td>
</tr>
</tbody>
</table>

Clinical and Interpretive
Clinical Information

Fetal lung maturity testing is used to determine the risk for developing respiratory distress syndrome (RDS) in infants born prematurely (32-39 weeks). The risk for developing RDS is inversely related to gestational age and is the most common cause of respiratory failure in neonates. RDS is associated with preterm birth due to insufficient production of pulmonary surfactant. Pulmonary surfactant is synthesized by type II pneumocytes. Surfactant consists of 90% phospholipids (primarily phosphatidylcholine and phosphatidylglycerol) and 10% proteins (surfactant proteins [SP]-A, SP-B, SP-C). Surfactant is packaged into lamellar bodies and is excreted into the alveolar space where it unravels and forms a monolayer on alveolar surfaces. Lamellar bodies can also pass into the amniotic cavity and, hence, are found in amniotic fluid. The surfactant functions to reduce the surface tension in the alveoli, preventing atelectasis. When surfactant is deficient, the small alveoli collapse and the large alveoli become overinflated and stiff, which has been associated with increased risk of developing respiratory distress. The status of fetal lung maturity is reflected in the concentration of surfactant in the form of phospholipids and lamellar bodies present in amniotic fluid. Lamellar bodies are similar in size to platelets and can be quantified on a hematology analyzer utilizing the platelet channel and used to estimate fetal lung maturity.

Reference Values

Immature: <15,000/mcL

Indeterminate: 15,000-50,000/mcL

Mature: >50,000/mcL


Interpretation

Amniotic fluid lamellar body counts (LBC) above 50,000/mcL are predictive of fetal lung maturity.

Amniotic fluid LBC below 15,000/mcL are suggestive of fetal lung immaturity and increased risk of neonatal respiratory distress syndrome (RDS).

The main value of fetal lung maturity testing is predicting the absence of RDS. An immature test result for fetal lung maturity is less reliable in predicting the presence of RDS.(1)

Cautions

Surfactant secretion into the amniotic fluid is minimal prior to 32 weeks gestation.

Fetal lung maturity testing is not indicated beyond week 39.

Specimens must not be frozen or centrifuged. Freezing and centrifuging the amniotic fluid falsely decreases the lamellar body count.

Clinical Reference

Test Definition: LBC
Lamellar Body Count, AF


Performance

Method Description
The Sysmex Automated Hematology Analyzer XN-9000 measures platelet count by the impedance method to quantify lamellar body counts. (Automated Hematology Analyzer/Transportation units XN series [XN-9000] Instructions for Use [North American Edition], Sysmex Corporation, Kobe, Japan. Feb 2014)

PDF Report
No

Day(s) and Time(s) Test Performed
Monday through Sunday; Continuously

Analytic Time
Same day/1 day

Maximum Laboratory Time
1 day

Specimen Retention Time
2 weeks

Performing Laboratory Location
Rochester

Fees and Codes

Fees
- Authorized users can sign in to Test Prices for detailed fee information.
- Clients without access to Test Prices can contact Customer Service 24 hours a day, seven days a week.
- Prospective clients should contact their Regional Manager. For assistance, contact Customer Service.

Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

CPT Code Information
83664

LOINC® Information
## Test Definition: LBC
Lamellar Body Count, AF

<table>
<thead>
<tr>
<th>Test ID</th>
<th>Test Order Name</th>
<th>Order LOINC Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>LBC</td>
<td>Lamellar Body Count, AF</td>
<td>19114-8</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Result ID</th>
<th>Test Result Name</th>
<th>Result LOINC Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>LBCC</td>
<td>Lamellar Body Count</td>
<td>19114-8</td>
</tr>
<tr>
<td>LBCI</td>
<td>Interpretation</td>
<td>59462-2</td>
</tr>
</tbody>
</table>